These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30655185)

  • 21. [Late onset Pompe disease: an analysis of 19 patients from Mexico].
    Sánchez-Sánchez LM; Martinez-Montoya V; Sandoval-Pacheco R; Torres-Octavo B; Anaya-Castro DM; Padilla-de la Torre O; Arellano-Valdez CA; Ávila-Rejón CA; Aguilar-Juárez PA; Espino-Pluma M; González-Santillanes Cruz A; Kazakova E; Martinez-Segovia RI; Olmos-Morfin D; Radillo-Díaz PF; Solís-Sánchez I; Vázquez Del Mercado-Espinosa M; Villarroel-Cortés CE; Velarde-Félix JS
    Rev Neurol; 2022 Sep; 75(5):103-108. PubMed ID: 35880963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
    Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
    Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
    Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New mutations and genotype-phenotype correlation in late-onset Pompe patients.
    Bekircan-Kurt CE; Güneş HN; Yildiz FG; Saka E; Tan E; Erdem-Özdamar S
    Acta Neurol Belg; 2017 Mar; 117(1):269-275. PubMed ID: 28032299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broad variation in phenotypes for common GAA genotypes in Pompe disease.
    Niño MY; In't Groen SLM; de Faria DOS; Hoogeveen-Westerveld M; van den Hout HJMP; van der Ploeg AT; Bergsma AJ; Pijnappel WWMP
    Hum Mutat; 2021 Nov; 42(11):1461-1472. PubMed ID: 34405923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
    Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
    Front Immunol; 2020; 11():1929. PubMed ID: 33013846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.
    Oba-Shinjo SM; da Silva R; Andrade FG; Palmer RE; Pomponio RJ; Ciociola KM; S Carvalho M; Gutierrez PS; Porta G; Marrone CD; Munoz V; Grzesiuk AK; Llerena JC; Berditchevsky CR; Sobreira C; Horovitz D; Hatem TP; Frota ER; Pecchini R; Kouyoumdjian JA; Werneck L; Amado VM; Camelo JS; Mattaliano RJ; Marie SK
    J Neurol; 2009 Nov; 256(11):1881-90. PubMed ID: 19588081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum.
    Musumeci O; Thieme A; Claeys KG; Wenninger S; Kley RA; Kuhn M; Lukacs Z; Deschauer M; Gaeta M; Toscano A; Gläser D; Schoser B
    Neuromuscul Disord; 2015 Sep; 25(9):719-24. PubMed ID: 26231297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.
    Herzog A; Hartung R; Reuser AJ; Hermanns P; Runz H; Karabul N; Gökce S; Pohlenz J; Kampmann C; Lampe C; Beck M; Mengel E
    Orphanet J Rare Dis; 2012 Jun; 7():35. PubMed ID: 22676651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of Pompe disease in China: a report from the Pompe registry.
    Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
    Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
    Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
    Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comprehensive Update on Late-Onset Pompe Disease.
    Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
    Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for late-onset Pompe disease in Internal Medicine departments in Spain.
    López-Rodríguez M; Torralba-Cabeza MA; de Pedro IP; Rivera A; Gil RS; Gómez-Belda A; de la Peña JLP; de Los Santos Moreno A; Selva-O'Callaghan A; Gárate IG; García AG; Hurtado R; de Ureta PT; Barba-Romero MÁ; Milisenda JC; Grau-Junyent JM;
    Orphanet J Rare Dis; 2023 Aug; 18(1):256. PubMed ID: 37653444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I; Hensel O; Zierz S
    Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-Onset Pompe Disease with Normal Creatine Kinase Levels: The Importance of Rheumatological Suspicion.
    Marotto D; Moschetti M; Lo Curto A; Spezzigu AM; Giacomarra M; Marsana EM; Zizzo C; Duro G; Colomba P
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease.
    Guevara-Campos J; González-Guevara L; Cauli O
    Neuromuscul Disord; 2019 Mar; 29(3):192-197. PubMed ID: 30595407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.